Expand Your Antibody Drug Development with bioSeedin’s Antibody Licensing Platform

Our Antibody Licensing Platform specializes in licensing out early-stage preclinical antibodies, and we are delighted to present to you our FXI/FXIa Bispecific Antibody asset as a prime recommendation.

FXI/FXIa Bispecific Antibody is Looking for

Project Profile

★ Project Name: FXI/FXIa BsAb (Fab-ScFv-FC)

★ Molecular type: Humanized antibody (mouse), IgG1

★ Molecular mechanism: Specifically binding to CD and A2 domain, can Comprehensive blocking of FXI pathway

★ Indications:Atrial Fibrillation/ Venous Thromboembolism

★ Project stage: Finished PK/PD

★ Cooperation demands: Project license-out

About FXI/FXIa

Pathology Evidence: People with severe congenital Factor XI deficiency appear to be protected from thrombosis, but very rarely have serious or spontaneous bleeding.
Clinical Evidence: Clinical trials of FXI inhibitors indicate that inhibition of Factor XI attenuates both venous and arterial thrombosis with no increase in bleeding.

Project Highlights

▶ In vitro: Good Binding Activity, Blocking of FXI/FXIa Pathway

Comprehensive blocking of FXI pathway: Targeting both CD and A2 domain, binding both FXI and FXIa, inhibiting FXIa activity, prevent FXI activation by FXIIa

BsAb Structure

Inhibits FXIa Activity in vitro

▶ In vivo: Exhibits Low Bleeding Risk in Cynomolgus Monkeys

Superior antithrombotic efficacy: Prolonged APTT Ratio~3, much better than most FXI monclonal antibody
Low bleeding risk: Equivelant with Abelacimab, better than DOACs